NCT06093334Completed
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
iMagINg of Chemotherapy-Induced Morphological and Functional Lung Changes in Childhood Acute Lymphoblastic Leukemia and Hodgkin's Disease
Source: ClinicalTrials.gov · Last updated 17 Dec 2024
Brief summary (registry, in English)
With increasing cure rates of childhood cancer there is growing recognition of late effects of treatments. However, there is a lack of non-invasive and child-friendly procedures that can indicate possible late damage. This study uses morphologic and free-breathing phase-resolved functional low-field (PREFUL) magnetic resonance imaging (MRI) to identify persistent pulmonary toxicity after treatment for childhood acute lymphoblastic leukemia (ALL), Hodgkin's disease (HD) and allogeneic stem cell transplantation. Furthermore, cardiopulmonary testing is performed by means of a pulmonary function test, echocardiography with strain analysis and spiroergometry.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 4 Oct 2023
- Start date
- 17 Oct 2023
- Primary completion date
- 9 Dec 2024
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
- NCT number
- NCT06093334
What you commit to
- Study type: Interventional
- Participants enrolled: 27
- From 17 Oct 2023 to the primary completion date, 9 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous lung surgery
- Previous lung surgery
- Previous lung surgery
Other illness
- Critical condition (requiring respiratory support, ventilation, oxygen, shock, symptomatic heart failure)
- General contraindications for MRI examinations (e.g. electrical implants such as cardiac pacemakers or perfusion pumps, etc.)
- Study arm: "Late therapeutic effects"
- Critical condition (requiring respiratory support, ventilation, oxygen, shock, symptomatic heart failure)
- General contraindications for MRI examinations (e.g. electrical implants such as cardiac pacemakers or perfusion pumps, etc.)
- Study arm: "Effects of hematopoietic stem cell transplantation"
- Critical condition (requiring respiratory support, ventilation, oxygen, shock, symptomatic heart failure)
- General contraindications for MRI examinations (e.g. electrical implants such as cardiac pacemakers or perfusion pumps, etc.)
Other
- Pregnancy, Lactation
- Known pleural or pericardial effusion
- Marked thoracic deformities/malformations
- Injuries that do not allow physical stress diagnostics
- Rejection of MRI imaging
- Pregnancy, Lactation
- Known pleural or pericardial effusion
- Marked thoracic deformities/malformations
- Injuries that do not allow physical stress diagnostics
- Rejection of MRI imaging
- Pregnancy, Lactation
- Known pleural or pericardial effusion
- Marked thoracic deformities/malformations
- Injuries that do not allow physical stress diagnostics
- Rejection of MRI imaging
Who the study is looking for
- Diagnosed acute lymphatic leukemia or Hodgkin's disease (HD)
- Completed induction therapy or radiotherapy
- Diagnosed acute lymphatic leukemia or Hodgkin's disease (HD)
- Completed intensive therapy or radiotherapy
- Diagnosed acute lymphatic leukemia
- Completed hematopoietic stem cell transplantation
Criteria the registry did not label
- Study arm: "Early therapeutic effects"
Age in the registry: 5 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Pediatrics and Adolescent Medicine Coordinator of this site? Confirm its status | Erlangen | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.